1 -( truns-[ 1Z3I ]Iodopropen-3-yl)-4-(4-cyanophenoxymethyl)pipidine has been prepared as a novel sigma receptor ligand for SPECT. This ligand was found lo be selective in v i m for the sigma receptor site (&(a) = 21.7 nM) when tested in a variety of neuroreceptor binding assays. The lipophilicity o
Radiosynthesis and in vivo study of [18F]1-(2-fluoroethyl)-4-[(4-cyanophenoxy)methyl]piperidine: a promising new sigma-1 receptor ligand
✍ Scribed by Jun Zhao; Raymond Chang; Patty Carambot; Rikki N. Waterhouse
- Publisher
- John Wiley and Sons
- Year
- 2005
- Tongue
- French
- Weight
- 124 KB
- Volume
- 48
- Category
- Article
- ISSN
- 0022-2135
- DOI
- 10.1002/jlcr.945
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
The novel sigma‐1 receptor PET radiotracer [^18^F]1‐(2‐fluoroethyl)‐4‐[(4‐cyanophenoxy)methyl]piperidine ([^18^F]WLS1.002, [^18^F]‐2) was synthesized (n=6) by heating the corresponding N‐ethylmesylate precursor in an anhydrous acetonitrile solution containing [^18^F]fluoride, Kryptofix K~222~ and potassium carbonate for 15 min. Purification was accomplished by reverse‐phase HPLC methods, providing [^18^F]‐2 in 59±8% radiochemical yield (EOB), with specific activity of 2.89±0.80 Ci/µmol (EOS) and radiochemical purity of 98.3±2.1%. Rat biodistribution studies revealed relatively high uptake in many organs known to contain sigma‐1 receptors, including the lungs, kidney, heart, spleen, and brain. Good clearance from normal tissues was observed over time. Blocking studies (60 min) demonstrated high (>80%) specific binding of [^18^F]‐2 in the brain, with reduction also noted in other organs known to express these sites. Copyright © 2005 John Wiley & Sons, Ltd.
📜 SIMILAR VOLUMES
## Abstract The neurotransmitter glutamate is thought to be crucially involved in a huge number of neurological and psychiatric disorders, such as Morbus Parkinson, Alzheimer's disease and schizophrenia. Aiming at an improved diagnostic tool for PET a new [^18^F]fluorine labelled NMDA receptor liga
## Abstract 2‐(4‐Methoxyphenyl)‐__N__‐(4‐methylbenzyl)‐__N__‐(1‐methylpiperidin‐4‐yl)acetamide (AC90179, **4**), a highly potent and selective competitive 5‐HT~2A~ antagonist, was labeled by [^11^C]‐methylation of the corresponding desmethyl analogue **5** with [^11^C]methyl triflate. The precursor
## Abstract 4‐Fluoro‐__N__‐{2‐[4‐(6‐trifluoromethylpyridin‐2‐yl)piperazin‐1‐yl]ethyl}benzamide is a full 5‐HT~1A~ agonist with high affinity (__pK__~__i__~=9.3), selectivity and a __c__ log __P__ of 3.045. The corresponding PET radioligand 4‐[^18^F]fluoro‐__N__‐{2‐[4‐(6‐trifluoromethylpyridin‐2‐yl)